tariffs
AstraZeneca Unveils $50 Billion U.S. Investment, Including Major Manufacturing Facility in Virginia
AstraZeneca; investment; United States; Virginia plant; manufacturing; R&D; tariffs; chronic diseases; job creation; pharmaceuticals
Big Pharma Braces for Potential 200% US Tariffs Amid Uncertainty
pharmaceutical industry; tariffs; Donald Trump; supply chains; onshoring; drug prices; manufacturing; healthcare system
Sanofi Announces $20 Billion US Investment Over Five Years
Sanofi; $20 billion investment; US pharmaceutical industry; manufacturing; research and development; tariffs; job creation; Big Pharma; domestic partnerships
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Trump Tariffs Could Delay Regulatory Filings for Half of Biotech Companies
Tariffs, Biotechnology, Regulatory filings, Manufacturing costs, Supply chain disruption
U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs
Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety